TY  - JOUR
AU  - Khalaf, D J
AU  - Aragon, I M
AU  - Annala, M
AU  - Lozano, R
AU  - Taavitsainen, S
AU  - Lorente, D
AU  - Finch, D L
AU  - Romero-Laorden, N
AU  - Vergidis, J
AU  - Cendon, Y
AU  - Oja, C
AU  - Pacheco, M I
AU  - Zulfiqar, M
AU  - Wyatt, A W
AU  - Olmos, D
AU  - Chi, K N
AU  - Castro, E
PY  - 2020
DO  - 10.1016/j.annonc.2020.06.006
UR  - http://hdl.handle.net/10668/15803
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy for metastatic castration-sensitive prostate cancer. The objective of...
LA  - en
KW  - HSD3B1
KW  - abiraterone
KW  - enzalutamide
KW  - genetic polymorphism
KW  - metastatic castration-resistant prostate cancer
KW  - therapeutic response biomarker
KW  - Abiraterone acetate
KW  - Androgen antagonists
KW  - Androstenes
KW  - Benzamides
KW  - Germ Cells
KW  - Humans
KW  - Male
KW  - Multienzyme complexes
KW  - Nitriles
KW  - Phenylthiohydantoin
KW  - Prospective studies
KW  - Prostate-specific antigen
KW  - Prostatic neoplasms, castration-resistant
KW  - Treatment outcome
TI  - HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
TY  - research article
VL  - 31
ER  -